The need for development of new therapeutic agents for polycystic ovary syndrome (PCOS) is urgent due to general lack of efficient and specialized drugs currently available. We aimed to explore the metabolic mechanism of PCOS and inferred drug reposition for PCOS by a subpathway-based method. Using the GSE34526 microarray data from the Gene Expression Omnibus database, we first identified the differentially expressed genes (DEGs) between PCOS and normal samples. Then, we identified 13 significantly enriched metabolic subpathways that may be involved in the development of PCOS. Finally, by an integrated analysis of PCOS-involved subpathways and drug-affected subpathways, we identified 54 novel small molecular drugs capable to target the PCOS-involved subpathways. We also mapped the DEGs of PCOS and a potential novel drug (alprostadil) into purine metabolism pathway to illustrate the potentially active mechanism of alprostadil on PCOS. Candidate agents identified by our approach may provide insights into a novel therapy approach for PCOS.
Introduction
Polycystic ovary syndrome (PCOS) is an endocrine disorder associated with hyperandrogenism and chronic anovulation. 1 It affects female reproductive performance as well as it has effects on female health. It was originally described in 1935 by Stein IF and Levental ML as a syndrome consisting of oligomenorrhea and obesity with enlarged polycystic ovaries. 1 It leads to infertility in 4% to 12% of women of childbearing age. [1] [2] [3] The etiology of this syndrome is not well defined. 1 The clinical and biochemical features of PCOS appear to be heterogeneous. 1, [3] [4] [5] Polycystic ovary syndrome is often characterized by oligo-and/or anovulation, hyperandrogenism (clinical and/or biochemical), and ultrasonographic features (polycystic ovaries). 2, 4 The diagnosis of PCOS is often based on a combination of clinical, biological, and ultrasound criteria. 6 There are several proposed diagnostic criteria for PCOS: National Institutes of Health (NIH) consensus criteria 1990, Rotterdam criteria 2003, and AES definition 2008. 6 The NIH consensus criteria noted the disorder as having (1) hyperandrogenism and/or hyperandrogenemia, (2) oligoovulation, and (3) exclusion of known disorders. 7 The AES definition focused on dealing with infertility management in PCOS. 8, 9 Currently, PCOS is defined by the 2003 Rotterdam criteria, which requires at least 2 of the 3 features for diagnosis: chronic anovulation, clinical and/or biochemical signs of hyperandrogenism, or polycystic ovaries. 10 Polycystic ovary syndrome not only represents a major cause of infertility, anovulation, hirsutism, and menstrual irregularities but also associates with metabolic abnormalities (insulin resistance) that may have severe influence for long-term health. 1, 3 The therapeutic management of PCOS includes nonpharmacological approaches (weight reduction) and pharmacological approaches directed at the symptoms. 3, 11, 12 For example, clomiphene is selected for inducing ovulation 3, 13 ; spironolactone and eflornithine are first-line agents for hirsutism 3, 11, 13 ; and insulin-sensitizing agents, metformin (Glucophage), are indicated for most patients with PCOS. 3, 12 Although there has been notable progression in the development of agents for PCOS therapies, the cellular mechanisms of response to therapy are not elucidated enough 1, 3 ; furthermore, the drugs for PCOS treatment are often directed at the different symptoms. 1, 3 Thus, special recommendations for treating PCOS are still lacking. 1, 3 However, the de novo development of drugs is time consuming, costly, and risky. Therefore, drug repositioning, namely, identifying new indication for known drugs, has become an effective and innovative approach in the development process, especially with the development of system biology and availability of public database. 14 For example, Gene Expression Omnibus (GEO) database and CMap database had provided numerous microarray data sets under disease or druginduced conditions. 15 Here, we presented a computational method for drug repositioning of PCOS based on metabolic subpathway analysis. We first explored the metabolic mechanism of PCOS and then identified known small molecular drugs capable of targeting the metabolic subpathways that were dysregulated in the development of PCOS. Although further evaluations are still needed, the candidate agents identified by our approach may provide great insights into improving therapeutic status for PCOS.
Results

Analysis of Differentially Expressed Genes Between Patients With PCOS and Healthy Controls
In order to explore the mechanism of PCOS, we obtained the expression profiles of PCOS samples and normal samples from GEO database (http://www.ncbi.nlm.nih.gov/geo/). We obtained the available microarray data set GSE34526 from the GEO database and then used fold change (FC) method to identify the differentially expressed genes (DEGs) between patients with PCOS and controls. 16 A total of 7027 genes were considered differentially expressed (see Methods and Materials section). All DEGs and corresponding FC values are shown in supplementary data set 1. The top 10 upregulated and downregulated genes are listed in Table 1 . To explore the biological functions of DEGs, we conducted Gene Ontology Biological Process functional enrichment analysis of the DEGs using the database for annotation, visualization, and integrated discovery (DAVID) tool 17 (http://david.abcc.ncifcrf.gov/). The statistically significant results are shown in supplementary data set 2 (P value < .01).
Exploring Mechanism of PCOS Based on Subpathway Enrichment Analysis
To explore mechanism of PCOS, we identified dysregulated metabolic subpathways using Subpathwayminer (http:// cran.r-project.org/src/contrib/Archive/SubpathwayMiner/). 18 We annotated the DEGs to entire metabolic pathways and subpathways (k ¼ 3). With the strict cutoff of P value less than .01, we identified 13 enriched metabolic subpathways corresponding to 5 entire metabolic pathways ( Table 2 ). These 13 metabolic subpathways have cross-talks in the corresponding entire pathways and were significantly related to development of PCOS.
Drug Reposition for PCOS
To identifying candidate small molecular drugs that were capable to target PCOS-related metabolic subpathways, we downloaded the global associations between drugs and metabolic subpathways from the article of Li et al, in which we identified 403 metabolic subpathways affected by 488 known drugs by also using Subpathwayminer with k ¼ 3 (see Methods and Materials section). 19 By integrating the 13 PCOS-related subpathways and these 403 drug-induced subpathways, we selected the overlapping subpathways that are related to both PCOS and small molecular drugs. Thus, we could assume that the small molecular drugs that affected the overlapping subpathway might play a role in perturbing the development of PCOS. A total of 54 small molecular drugs were identified (Table 3) .
We then built a network between these repositioned drugs and the overlapping metabolic subpathways by integrating the relationships mentioned earlier ( Figure 1 ). In this network, some small drugs could perturb many metabolic subpathways (eg, pergolide and alprostadil perturbed 7 and 6 subpathways), respectively, while some small molecular drugs could perturb only a few subpathways ( Figure 1 ).
Pathway Annotation of DEGs of Alprostadil and PCOS in Purine Metabolism
To elucidate the potential involvement of alprostadil in PCOS in detail, we mapped the DEGs of PCOS and alprostadil into the pathway of purine metabolism (path:00230) using the ''user data mapping'' tool in Kyoto Encyclopedia of Genes and Genomes (KEGG) database (http://www.genome.jp/kegg/). The DEGs of alprostadil were downloaded from the supplementary data sets in studies of Li et al. 19 The results are shown in Figure 2 . We found that many enzymes were perturbed by both alprostadil (red pentagram) and PCOS (red rectangle), including phosphodiesterase (PDE; blue circle).
Discussion
Analysis of disease gene expression profiling could help us reveal the underlying mechanism of complex diseases and provide us potential targets for improving therapeutic intervention.
In this research, we used the gene expression profile downloaded from GEO to explore the underlying mechanism of development of PCOS. This gene expression profile was based on human granulosa cells (GCs) which was anatomically proximal to the ovarian germ cells. Their functional communication with oocytes was not only essential for oocyte and follicular growth but also crucial for fertility. 20 A total of 7027 DEGs were identified between PCOS samples and healthy controls. Subpathway mining result showed that 13 metabolic subpathways corresponding to 5 entire pathways were dysfunctional in PCOS. Then, we identified the potential therapeutic agents for PCOS using a computational drug reposition method. A total of 54 small molecules were identified, which may play a role in perturbing the development of PCOS.
Currently, majority of pathway-enrichment approaches commonly focus on the entire pathways. 18 However, analysis of subpathways, which focuses on certain local areas of pathways, can identify more subtle subpathways that are neglected by entire pathways analysis. It may be more suitable and flexible than entire pathways for identification of disease mechanism and drug responses. 18, 19 In this study, we identified 13 subpathways from 5 KEGG metabolic pathways. On one hand, some of these subpathways have well-documented metabolic and hormonal effects in PCOS. For example, the most significant subpathway, inositol phosphate metabolism (path:00562_6; P value ¼ .000387), has been reported to be involved in the pathogenesis of insulin resistance and administration of myoinositol (MYO) has demonstrated to improve the insulin receptor activity for potentially restoring spontaneous ovulatory function in most of women with PCOS. 2, 21, 22 Another example is starch and sucrose metabolism (path:00500_9; P value ¼ .006531). The metabolism of sucrose is found to be impaired in ovarian capsule with polycystic ovarian disease, resulting in lower level of androgenbinding protein compared with normal ovarian capsule. 23 In this subpathway, some DEGs have been reported to associate with PCOS. For example, GYS2 (FC ¼ 2.5) was identified as a novel genetic factor for PCOS by a genome-wide association study. 24 On the other hand, the roles of other pathways in PCOS have not been well defined previously. But some key enzymes or metabolites were found to be related to PCOS. For example, NAD(P)H, a metabolite in nicotinate and nicotinamide metabolism (path:00760), was found to have a higher level in oocytes of patients with PCOS. 25 We also note that 5 of 13 enriched subpathways belonged to the entire pathway of purine metabolism (path:00230), which was not found to have direct relation to 
PCOS previously.
But it is reported that some key enzymes (ie, adenosine deaminase) of purine metabolism are commonly associated to bioactivity of insulin and play a contributory role in patients with insulin resistance which appears in majority of women with PCOS. 26 We then identify a group of known drugs with potential novel therapeutic efficacy for PCOS. A total of 54 small molecules, which have common subpathways with PCOS, were identified including pergolide (number of overlaps ¼ 7) and alprostadil (number of overlaps ¼ 6). Pergolide, an ergotderived dopamine D 2 receptor agonist, is used for pituitary pars intermedia dysfunction. 27 Although we could not find the direct reports of pergolide involvement in PCOS, it is related to insulin resistance and used to treat type 2 diabetes mellitus in animal models. Alprostadil, known pharmaceutically as prostaglandin E1 (PGE1), has vasodilatory properties and is used widely in various clinical settings, and prostaglandins produced by ovarian GCs are essential for ovulation. 28, 29 Although there are a few reports about the associations between PGE1 and PCOS, alprostadil has not been used as a therapeutic management for PCOS clinically, and the underlying mechanism is not yet clear. From Figure 1 , we find that 5 of 6 overlap subpathways belong to the ''Purine metabolism'' (path:00230). For detailed elucidation of potential involvement of alprostadil in PCOS, we mapped the DEGs of PCOS and alprostadil into the pathway of purine metabolism (path:00230; Figure 2 ). We found that lots of PCOS-involved genes are also perturbed by alprostadil. Interestingly, of these overlapped genes, PDEs (blue circle in Figure 2 ) are found to have genetic variation in PCOS and it participates in the cyclic adenosine monophosphate (cAMP) degradation, while cAMP can be produced by adenylate cyclase after activation by PGE1. 30, 31 These findings indicate potential therapeutic targets for PCOS.
We still note that there were some limitations in our studies. There were only small molecular drugs in our studies. The scope of candidate drugs will be expanded by integrating more drug-affected data from different resources. Also, further experimental verification and population-based studies are still needed to make these agents safely available clinically. Although our method and data are far from completeness, our study still presents a bioinformatics approach based on subpathway analysis to infer drug reposition for PCOS and may provide insights into a novel therapy approach for PCOS.
Methods and Materials
Microarray Data and DEGs Analysis
The microarray data of GSE34526 was obtained from GEO database (http://www.ncbi.nlm.nih.gov/geo/) in the National Center of Biotechnology Information. 32 This profile was based on human GCs isolated from ovarian aspirates of normal women and women with PCOS. 16 A total of 7 patients with PCOS and 3 normal women were profiled using the Affymetrix Human Genome U133 Plus 2.0 Array (HG-U133_Plus_2) platform. 16 We downloaded the raw microarray data and the probe annotation files for further analysis. At first, we calculated the FC values for each probes. Then, we converted each probes into gene Entrez Gene IDs. If 1 gene matched more than 1 probes, the expression value of this gene was computed by taking the average expression value of all corresponding probes. Finally, the genes with FC value more than 2 or less than 0.5 were identified as DEGs.
Obtainment of Subpathways by SubpathwayMiner
To obtain the perturbed subpathway under PCOS, we used the SubpathwayMiner software package which is a flexible subpathway identification method. 18 In this software, the pathway structure data with KGML format provided by KEGG is converted to R graph objects. 33 Then, the enzymes are considered as nodes and 2 nodes in an undirected graph are connected by an edge if there is a common compound in the reactions of the corresponding enzymes. This software package can transform the entire pathway into subpathways by ''k-clique'' method. 18 In social network analysis, a k-clique in a graph is defined as a subgraph in which the distance between any 2 nodes is no greater than a parameter, k. 18 Here, we set k ¼ 3, and this parameter setting means that the distance among enzymes in 1 subpathway is not greater than 3.
We then imported the DEGs (from microarray data of GSE34526) into SubpathwayMiner, and this software could identify significantly enriched subpathways. The P value less than .01 is chosen as the cutoff criterion for statistically significant subpathways.
The Associations Between Drugs and Metabolic Subpathways
To find the novel drugs that may play a role in the PCOSinvolved subpathways, we obtained the global associations between drugs and metabolic subpathways from the article of Li et al. 19 They first downloaded microarray data for each small molecular drug from the CMap database and identified the DEGs for each drug by a cutoff with |FC| > 1 (after logarithmic transformation). 15 Then, they identified drug-affected subpathways for each drug and whether the corresponding drug-affected genes could be significantly enriched to the subpathways by the SubpathwayMiner software package (P value < .01). 19 Finally, this article obtained 403 metabolic subpathways corresponding to 488 drugs.
Identification of Potential Drugs for PCOS
In the article of Li et al, they identified 403 drug-related metabolic subpathways. 19 In this article, we identified 13 PCOS-related metabolic subpathways. The overlaps of the above-mentioned 2 sets of metabolic subpathways were selected. We found that all 13 PCOS-related subpathways were included in 403 drug-related subpathways. These 13 overlapping subpathways were not only drug affected but also involved in the development of PCOS. They were corresponding to 54 drugs according to the drug-metabolic subpathway associations in the article of Li et al. 19 
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